Can Kerendia (Finerenone) Cause Hyponatremia and Diarrhea?
Yes, Kerendia (finerenone) can cause hyponatremia, which is listed as an adverse reaction occurring in ≥1% of patients, but diarrhea is not a documented adverse effect of this medication. 1
Documented Adverse Reactions
According to the FDA prescribing information, the adverse reactions occurring in ≥1% of patients on Kerendia and more frequently than placebo are specifically:
- Hyperkalemia (most common and clinically significant)
- Hypotension
- Hyponatremia
Diarrhea is notably absent from the documented adverse reaction profile in both the FDA label and the major clinical trials (FIDELIO-DKD, FIGARO-DKD, and the pooled FIDELITY analysis involving 13,171 patients). 2, 3
Clinical Context: Hyponatremia
While hyponatremia is listed as an adverse reaction, the clinical trials and guidelines focus predominantly on hyperkalemia as the primary electrolyte concern with finerenone:
- In FIGARO-DKD, hyperkalemia occurred in 10.8% of finerenone patients vs. 5.3% with placebo 4
- Only 1.2% discontinued due to hyperkalemia despite routine monitoring 2
- Hyponatremia, though documented, receives minimal emphasis in the safety data, suggesting it is less clinically problematic than hyperkalemia
Important Safety Monitoring
The key electrolyte to monitor with finerenone is potassium, not sodium:
- Check potassium at 1 month after initiation, then every 4 months 5
- Hold finerenone if K+ >5.5 mmol/L 5, 6
- Restart at lower dose when K+ ≤5.0 mmol/L 5
Common Pitfall
Do not confuse finerenone with steroidal mineralocorticoid receptor antagonists (like spironolactone), which have different adverse effect profiles. The older ACC/AHA guideline 7 discusses diarrhea as a cause of dehydration that should be "addressed emergently" in patients on aldosterone antagonists, but this refers to diarrhea as an external factor causing electrolyte disturbances, not as a drug side effect.
Bottom Line
Hyponatremia: Yes - documented FDA-labeled adverse reaction
Diarrhea: No - not a recognized adverse effect of finerenone based on extensive clinical trial data and FDA labeling